Helus Pharma Inc. (NASDAQ:HELP) (Cboe CA: HELP) ("Helus Pharma" or the "Company"), a clinical-stage pharmaceutical company committed to improving the treatment landscape in mental health conditions through the development and commercialization of novel serotonergic agonists ("NSAs"), today announced positive topline results from APPROACH, its Phase 3 pivotal study evaluating HLP003 (deuterated psilocin), as an adjunctive treatment for adults with major depressive disorder ("MDD").
HLP003 achieved statistically significant and clinically meaningful results in the primary, key secondary and other secondary endpoints starting as early as Day 2 and these were maintained at all time points.
At the primary endpoint of 6 weeks, the least squares ("LS") mean reduction from baseline in the MADRS total score for HLP003 was 19.5 points versus 11.9 points for placebo (LS mean difference = -7.6 points, p<0.0001, effect size=0.653).
The rapid onset of action with HLP003 was demonstrated with statistically significant LS mean MADRS reductions as early as Day 2 of 16.1 points versus 11.0 points for placebo (LS mean difference = -5.0 points, p=0.0013, effect size=0.438). This effect was durable with an LS mean reduction from baseline in the MADRS total score for HLP003 of 16.9 points versus 9.9 points for placebo (LS mean difference = -7.0 points, p<0.0001, effect size=0.581) at the key secondary endpoint of 12 weeks.
"The large unmet need for patients with major depressive disorder who continue to experience persistent symptoms underscores the importance of new rapid-acting and well-tolerated adjunctive treatment options," said Michael Halstead, Chief Executive Officer of Helus Pharma. "We believe these data demonstrate a therapeutic profile that has the potential to meaningfully improve outcomes for patients and strengthen our momentum as we continue to progress HLP003 toward regulatory approval and potential commercialization."
Other Efficacy Results
HLP003 demonstrated statistically significant and clinically meaningful improvements in response and remission rates as an adjunctive therapy, starting as early as Day 2 and maintained at all time points:
HLP003
(N=112) Placebo
(N=110) p-value
Response rate (50% reduction from baseline)
at Day 2 50.0% 23.6% 0.0002
at Week 6 56.3% 28.2% <0.0001
at Week 12 45.5% 19.1% <0.0001
Remission rate (MADRS total score of ≤10)
at Day 2 39.3% 15.5% 0.0002
at Week 6 50.9% 18.2% <0.0001
at Week 12 40.2% 15.5% <0.0001
Additionally, HLP003 demonstrated statistically significant improvements on the Clinical Global Impression Scale compared with placebo starting as early as Day 2 and maintained at all time points.
"The results from the APPROACH study set a new benchmark for what may be achievable with adjunctive treatment in major depressive disorder," said Roger S. McIntyre, M.D., FRCPC, Professor of Psychiatry and Pharmacology, University of Toronto. "The magnitude of benefit observed in this study is highly compelling and has the potential to redefine expectations among clinicians treating patients who continue to experience depressive symptoms while on an anti-depressant."
Approximately two-thirds of patients with depression do not achieve remission with first-line antidepressant treatment.1 For patients who experience an inadequate response, adjunctive therapy is a commonly used treatment strategy. By adding a therapy to an existing antidepressant regimen, clinicians may be able to enhance treatment response while avoiding the need for antidepressant discontinuation, medication washout periods, or the potential withdrawal symptoms associated with switching treatments.
Safety and Tolerability
HLP003 was generally well tolerated in the APPROACH study. Most adverse events were mild to moderate in severity, transient, and primarily limited to the day of dosing. There were three HLP003 treatment-related serious adverse events in the study. No new safety signals were identified.